Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Dexamethasone for Cerebral Toxoplasmosis
NCT04341155Phase 2Recruiting
- Sponsor
- Universitas Padjadjaran
- Start
- Apr 2021
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cerebral toxoplasmosis (TE) comparing Dexamethasone with Placebo (2 arms). Primary endpoint: Mortality at 90 days. Started Apr 2021; status: recruiting.
02
Drugs
dexamethasone
03
Conditions
cerebral toxoplasmosis (TE)
Beyond the preview
Go deeper on NCT04341155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341155.